Ayala Pharmaceuticals

ESMO 2022 movers – KRAS backfires
EP Vantage
Thu, 09/15/22 - 10:12 am
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
What pandemic? Biotech floats break records
EP Vantage
Wed, 07/8/20 - 10:37 am
biotech
IPOs
ADC Therapeutics
Akouos
Applied Molecular Transport
Avidity Biosciences
Ayala Pharmaceuticals
Forma Therapeutics
Fusion Pharmaceuticals
Generation Bio
Hyloris Pharmaceuticals
Lantern Pharma
ORIC Pharmaceuticals
Pliant Therapeutics
PolyPid
Repare Therapeutics
Royalty Pharma
SutroVax
Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs
Xconomy
Fri, 05/8/20 - 10:30 am
Ayala Pharmaceuticals
IPOs
cancer
Bristol-Myers Squibb
Oncology biotech Ayala Pharmaceuticals sets terms for $50 million IPO
NASDAQ
Mon, 05/4/20 - 10:41 am
Ayala Pharmaceuticals
Israel
small molecule drugs
cancer
IPOs
Trifecta of clinical stage biotechs unveil IPO plans, braving Wall Street's coronavirus panic
Endpoints
Mon, 03/9/20 - 10:48 am
coronaviruses
COVID-19
IPOs
Zentalis Pharmaceuticals
Lyra Therapeutics
Ayala Pharmaceuticals
Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Fierce Biotech
Sun, 06/2/19 - 01:28 pm
ASCO 2019
Ayala Pharmaceuticals
Novartis
triple negative breast cancer
AL101
Novartis powers Notch cancer biotech Ayala to $30M series B
Fierce Biotech
Wed, 05/29/19 - 10:28 am
Novartis
Ayala Pharmaceuticals
AL101
adenoid cystic carcinoma